A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Journal of Cardiology and Cardiovascular Medicine
Dual antiplatelet therapy (DAPT) combining aspirin and a P2Y12 receptor inhibitor has been consistently shown to reduce recurrent major adverse cardiovascular events (MACE) in patients with acute coronary syndrome (ACS) or undergoing percutaneous coronary intervention (PCI) for stable coronary artery disease (CAD) compared with aspirin monotherapy but at the expense of an increased risk of signifi cant bleeding. Among patients with stable CAD undergoing PCI with drug-eluting stents (DES),doi:10.29328/journal.jccm.1001088 fatcat:kel7czizbracbpkzb6nuxribvy